mitochondrial myopathy (MELAS with an A3243G mutation)
Conditions
Interventions
Intervention type:DRUG
Name of intervention:L-arginine
Dose form / Japanese Medical Device Nomenclature:INJECTION
Route of administration / Site of application:INTRAVENOUS DRIP
Dose per administration
Sponsors
Kurume University
Yasutoshi Koga
Hidefumi Nakamura, Clinical Trial Center, National Research Center of Pediatrics and Child Health, Japan
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: MELAS who fulfilled the Japanese diagnostic criteria of MELAS and has an A3243G mutation, and who come to the hospital within 6 hours after the onset of stroke-like episodes
Exclusion criteria
Exclusion criteria: 1) patient who has status epileptics or having unconsiousness 2) patient who has dementia or bed ridden status 3) patient who has more than 7% of HbA1c or receiving insulin therapy 4) patient who has septic state 5) patient who has arginase deficiency 6) patient who has hepatic or renal failure 7) patient who has cardiac infarction or has the history of cardiac infarction 8) patient who received the nitric-oxide related drug 1 week before their enrolment 9) patient who receive the edaravon 12 hours before enrolment 10) patient who is pregnant or possible to be pregnant 11) patient who has been enrolled to other clinical trial within 6 months. 12) patient whose enrolment is thought to be not adequate by responsible doctor
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| headache, vomit | — |
Secondary
| Measure | Time frame |
|---|---|
| convulsion, unconsciousness, blindness | — |
Countries
Japan
Contacts
Public ContactYasutoshi Koga
Kurume University
Outcome results
None listed